| DB ID | MyCo_3517 |
| Title | Serial change in serum biomarkers during treatment of Non-HIV Pneumocystis pneumonia |
| Year | 2019 |
| PMID | 31186197 |
| Fungal Diseases involved | Pneumocystis pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | spp. |
| Organism | Pneumocystis spp. |
| Ethical Statement | This study was approved by the Internal Review Board (IRB) of Toho University Omori Medical Center (IRB approval No. M18119). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | A total of 65 patients with non-HIV PCP were treated during the period from January 2007 through September 2018 at Toho Uni- versity Omori Medical Center. This single-center retrospective cohort study analyzed the clinical records of these 63 patients. On the basis of 60-day survival after the start of PCP treatment, the patients were classi ed as survivors (n¼ 49) and nonsurvivors (n¼ 14). |
| Cohort No. | 63 |
| Age Group | 48-75 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis pneumonia (PCP), a pulmonary infection caused by Pneumocystis jirovecii (P. jirovecii), can manifest as an opportu-nistic infection in persons with human immunode ciency virus (HIV) or other causes of immunode ciency. Persons with autoim- mune disorders, recipients of organ transplants, and patients with malignant neoplasms often receive massive doses of corticosteroids and immunosuppressants for treatment or palliative care. The prevalence of PCP has thus been increasing in patient groups other than HIV-infected patients. |
| Technique | Analytic |
| Analysis Method | Fungitec G test-WAKO turbidimetric assay |
| ELISA kits | Fungitec G test Kit (Seikagaku Corporation, Tokyo, Japan), KL-6 ELISA Kit (Eisai Corporation, Tokyo, Japan) , SP-D ELISA Kit (Yamasa, Chiba, Japan). |
| Assay Data | WAKO turbidimetric assay (Wako Pure Chemical Industries, Tokyo, Japan), |
| Validation Techniques used | Fungitec G test-WAKO turbidimetric assay, ELISA |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
